| Download | - View final version: SERS-based assay for multiplexed detection of cross-reactivity and persistence of antibodies against the spike of the native, P.1 and B.1.617.2 SARS-CoV-2 in non-hospitalised adults (PDF, 5.1 MiB)
|
|---|
| DOI | Resolve DOI: https://doi.org/10.1039/D2SD00073C |
|---|
| Author | Search for: Chisanga, Malama1; Search for: Stuible, Matthew2; Search for: Gervais, Christian2ORCID identifier: https://orcid.org/0000-0002-0519-3054; Search for: L'Abbé, Denis2; Search for: Cass, Brian2; Search for: Bisson, Louis2; Search for: Pelletier, Alex2; Search for: Lord-Dufour, Simon2; Search for: Durocher, Yves2; Search for: Boudreau, DenisORCID identifier: https://orcid.org/0000-0001-5152-2464; Search for: Trottier, Sylvie3; Search for: Pelletier, Joelle N.4; Search for: Masson, Jean-Francois1ORCID identifier: https://orcid.org/0000-0002-0101-0468 |
|---|
| Affiliation | - Department of Chemistry, Québec Centre for Advanced Materials (QCAM), Regroupement Québécois sur les Matériaux de Pointe (RQMP), and Centre Interdisciplinaire de Recherche sur le Cerveau et l'Apprentissage (CIRCA), Université de Montréal, CP 6128 Succ. Centre-Ville, Montreal, Québec, H3C 3J7, Canada
- National Research Council of Canada. Human Health Therapeutics
- Centre de Recherche du Centre Hospitalier Universitaire de Québec and Département de Microbiologie-Infectiologie et d'Immunologie, Université Laval 2705, Boulevard Laurier, Québec, QC G1V 4G2, Canada
- Department of Chemistry, Department of Biochemistry and PROTEO, Québec Network for Research on Protein Function, Engineering and Applications, Université de Montréal, CP 6128 Succ. Centre-Ville, Montreal, Québec, H3C 3J7, Canada
|
|---|
| Funder | Search for: Canada Foundation for Innovation; Search for: Canadian Institutes of Health Research; Search for: Natural Sciences and Engineering Research Council of Canada; Search for: National Research Council Canada |
|---|
| Format | Text, Article |
|---|
| Abstract | Monitoring antibody response to SARS-CoV-2 is critical for assessing the humoral response, especially important considering the emergence of multiple SARS-CoV-2 variants of concern (VOCs). Herein, we developed rapid and highly sensitive microfluidics-integrated multiplexed SERS to simultaneously screen multiple anti-spike immunoglobulin isotypes (IgG, IgA and IgM) to establish the level of cross-reactivity and the persistence of anti-spike immunoglobulins in immune patient sera for the native, P.1 and B.1.617.2 strains of SARS-CoV-2 virus. The study was performed on 24 non-hospitalised adults with laboratory diagnosed COVID-19 and had fully recovered before the emergence of the P.1 and B.1.617.2 mutants. We report seroconversion and cross-protection of IgG, IgA and IgM antibodies against the spike proteins of the native SARS-CoV-2, and the P.1 and B.1.617.2 VOCs in sera collected longitudinally at 3 weeks and 8 weeks following a PCR-positive test. Although high levels of IgG, IgA and IgM were detected against the native strain, immune responses of cross-reactive binding antibodies against the spike protein of the VOCs decreased significantly. Our study revealed that in addition to exhibiting the highest seropositivity rates (>97%), IgG responses were maintained up to 8 weeks post-diagnosis, irrespective of the tested spike protein. In contrast, the relatively high seropositivity rates of IgA and IgM (>86% and >80%, respectively) detected at 3 weeks post diagnosis decayed rapidly, approaching baseline by week 8 post-diagnosis, and this observation was congruent with binding affinities of IgA and IgM. We also demonstrate that the levels of anti-spike antibodies correlated with patient age, with the oldest individuals (>70 years) displaying highest antibody binding responses across the spike antigens. Collectively, our results illustrate the potential applicability of multiplexed SERS assays to screen past COVID-19 and to assess cross-protective humoral immunity against VOCs. |
|---|
| Publication date | 2022-07-14 |
|---|
| Publisher | Royal Society of Chemistry |
|---|
| Licence | |
|---|
| In | |
|---|
| Language | English |
|---|
| Peer reviewed | Yes |
|---|
| Export citation | Export as RIS |
|---|
| Report a correction | Report a correction (opens in a new tab) |
|---|
| Record identifier | fd4695db-7ef1-4031-9e1f-67dc322c6e0a |
|---|
| Record created | 2024-03-19 |
|---|
| Record modified | 2025-11-03 |
|---|
